#Paris #France #Astraveus #Lakhesys #France 2030

Astraveus Secures Funding to Transform Cell Therapy Manufacturing

In a significant boost to the biotechnology industry, Astraveus SAS has announced that it has secured €7.1 million in funding from the French government. Specifically categorized as non-dilutive funding, this financial support is part of the broader France 2030 investment program aimed at fostering innovation and bolstering economic growth within France.

Astraveus, renowned for its innovative approach in cell therapy manufacturing, applied for the funding through the Première usine initiative, which is managed by Bpifrance. This initiative seeks to fast-track industrialization projects initiated by startups, providing a platform for new companies to emerge and stabilize their operations within the market.

The funding will facilitate the establishment of state-of-the-art manufacturing infrastructure that focuses on producing microfluidic consumables. This is a pivotal step towards launching the Lakhesys Benchtop Cell Factory™, which promises to enhance the efficiency and scalability of cell therapy production. With this advancement, Astraveus aims to revolutionize how cell therapies are processed, making them more accessible and cost-effective for patients around the globe.

Dr. Jérémie Laurent, the CEO of Astraveus, expressed his excitement regarding the funding, stating, “This additional funding awarded by the French State through its France 2030 program is a testament to our innovative approach and dedication to revolutionizing cell therapy manufacturing. We are thrilled to charge forward in establishing our industrialization infrastructure in Paris.”

The financial backing comes at a crucial time as the company looks to further its mission of delivering high-quality cell therapies at significantly reduced costs. By leveraging cutting-edge microfluidic technology, Astraveus is not only focusing on process optimization but also on ensuring the scalability of its operations, thus making advanced therapies more attainable for those in need.

Founded in 2016 by Jérémie Laurent at the esteemed Saint-Louis Hospital in Paris, Astraveus has consistently aimed to pioneer advancements in bioprocessing technology. The company's commitment centers on enhancing the development and manufacturing of cell therapies, striving to create solutions that are not just innovative but also widely accessible.

Vision for the Future

With the support from the French government, Astraveus intends to position itself at the forefront of biotechnology innovations. The funding will allow them to achieve significant milestones in manufacturing capacities, leading to faster turnaround times for producing therapies that could change lives. The Lakhesys Benchtop Cell Factory™ represents not just a product but a holistic vision for the future of healthcare—where advanced therapies are available to everyone on a global scale.

In summary, the €7.1 million secured from the French State is not merely a financial transaction; it symbolizes a crucial partnership between public and private sectors aimed at fostering technological progress within the life sciences field. Astraveus plans to utilize this opportunity to not only grow its operations but to also inspire future generations of biotechnologists and innovators in the cell therapy space.

For more information on their ongoing projects, you can visit their official website: Astraveus.